Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice - Wikidata - awgldk - TriplyDB

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

http://www.wikidata.org/entity/Q26766728

about

Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.[Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia].Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.Intragastric Botolinum Toxin-A Injection as a Treatment for Obesity in Comparison to Gastric Balloon.Botulinum neurotoxin formulations: overcoming the confusion.Unilateral Botulinum Neurotoxin-A Injection into the Striatum of C57BL/6 Mice Leads to a Different Motor Behavior Compared with Rats Treatment of non-odontogenic orofacial pain using botulinum toxin-A: a retrospective case series study

P2860

Q39207459-E9775C4F-2477-4B97-B63A-D488E8B93EB4 Q40421111-801437CA-4096-4A76-83BD-D2790C6BFBD4 Q47253498-DC911DD1-6AED-461F-BA3E-CC1D544E534F Q48156555-E73BED95-D9D3-402B-BC54-D16F79C0BCA8 Q55260245-EDCFD8D3-8BF4-4BD6-ACDA-F47F80D2F609 Q57515344-54B2A092-7623-47A3-8EAC-3CF047D95DAD Q58798782-013522D1-5A28-41BD-9F80-0EEA6CB7EBEB

P2860

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

http://www.wikidata.org/entity/Q26766728

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@ast

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@en

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@nl

type

label

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@ast

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@en

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@nl

prefLabel

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@ast

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@en

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@nl

P1433

Q26766728-BF1BA0F1-B4A3-4F46-A763-E95B8E17DE9A

P1476

Q26766728-CA8E80D2-BFF5-4913-BA0E-D45717B7D799

P2093

Q26766728-612DC3D5-0A04-46BE-9DFB-3C4FACE009C7

P275

Q26766728-A1CBDAAC-D1E2-44F8-88B1-1598A7F841B2

P2860

Q26766728-0B74C682-4726-4B37-AEDF-27BE41CE76ED

Q26766728-17D6BA80-4F77-4217-AF13-E8EAF94A6F0E

Q26766728-19B73F4F-1513-41B8-8001-ACEF370AB074

Q26766728-31B0FD66-79AC-4D92-97C6-ADF0479D3178

Q26766728-3AD1E28B-FF17-492C-AB90-1B4F6B9CC935

Q26766728-42F171C8-34FA-4C53-8294-5B6BE901B723

Q26766728-43F666C2-CD95-4EAC-B252-0E1C928EC11D

Q26766728-4995386E-F5DF-4BF2-B885-7C8D1723DB5E

Q26766728-4D82AC7C-7C2E-4215-8E83-DB044CA45724

Q26766728-50E0493A-C0AE-4479-B1F0-CB389F0172FB

P304

Q26766728-63B20813-A725-4B21-9C20-524B82A654E1

P31

Q26766728-00EE9E59-E3C0-4291-854F-8F15D0590A3A

Q26766728-75FFAA01-543C-44EA-97CE-9A9B937C310E

P356

Q26766728-66C94E55-889D-4B6B-A718-91FBE83E25CD

P407

Q26766728-195B52C6-1699-4C17-8452-1AB684B1D24D

P433

Q26766728-DBC5C965-DBA0-4AFD-8D86-731F098AFC10

P478

Q26766728-1B6859DC-FA93-4E8C-A189-7A9C21CF87B4

P50

Q26766728-694A72C6-7422-425A-9BB8-AC68548AFA47

P577

Q26766728-C681E25C-698C-4AA6-ADB8-21C140FC97EA

Q26766728-EE11004A-1A55-409A-AD2B-0304C188B94E

P5875

Q26766728-D449640B-442D-4656-B6F8-52923835BE9E

P698

Q26766728-0D4AAF7D-E001-4222-801C-CBA9BA3AA2CA

P921

Q26766728-534FA5F3-8764-41B2-A3C2-77FAC8C1372B

Q26766728-E37B38DE-07E4-4C85-BC65-62492C088165

P932

Q26766728-1A08C1AF-D7BF-4C52-9BB3-34F7E11FFDBE

P356

P1433

P1476

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

@en

P2093

Francesco Scaglione

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Clinical relevance of botulinum toxin immunogenicity

Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions

Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value.

Dose standardisation of botulinum toxin

Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm

Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.

Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Does reducing spasticity translate into functional benefit? An exploratory meta-analysis.

Basic immunological aspects of botulinum toxin therapy.

Clinical comparability of marketed formulations of botulinum toxin.

P304

65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/TOXINS8030065

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Scaglione

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297607682

http://www.w3.org/2001/XMLSchema#string

P698

26959061

http://www.w3.org/2001/XMLSchema#string

P921

bacterial protein

P932

4810210

http://www.w3.org/2001/XMLSchema#string